Flexpharm

Flex Pharma, LLC is a clinical-stage specialty pharmaceutical company focused on transforming the formulation and delivery of complex oncology therapeutics. Utilizing its proprietary ElectroNanoSpray (ENS) platform technology—a non-thermal spray drying process that uses electric-field forces—the company reformulates established oncology molecules to enhance bioavailability, eliminate food effects, and overcome pH-dependent solubility challenges. Flex Pharma's innovative approach is validated by the FDA approvals of Phyrago (dasatinib) and Cavhanza (nilotinib Orally Disintegrating Tablets), the latter developed in partnership with Cycle Pharmaceuticals to allow flexible dosing with acid-reducing agents. The company is also advancing a robust pipeline of early-stage oncology assets to address significant unmet medical needs within the oncology landscape.